-
EACS 2025 Opens in Paris: An Exclusive Interview with EACS President Prof. Milosz Parczewski
Prof. Milosz Parczewski Pomeranian Medical University, Szczecin, Poland Miłosz Parczewski has received the MD diploma at the Pomeranian Medical University, Szczecin, Poland in 2002 and was granted a Ph.D diploma…
-
A New Breakthrough in Urothelial Carcinoma Treatment — Professor Dingwei Ye from Fudan University Cancer Hospital Leads a Groundbreaking Clinical Study
Approximately 5% of urothelial carcinoma (UC) patients present with distant metastasis at diagnosis, and 30% of early-stage patients relapse or develop metastasis despite active treatment. With the emergence of antibody-drug conjugates (ADCs), the median survival of advanced UC patients has extended to 31.5 months. However, the overall survival remains suboptimal. To address this challenge, Professor…
-
ESMO 2025丨An Academic Feast Awaits — Highlights from the Uro-Oncology Field You Won’t Want to Miss!
At the highly anticipated ESMO Congress, a wealth of cutting-edge advances will be presented, with uro-oncology standing out as one of the most vibrant and fast-evolving fields. This year, 22 Late-Breaking Abstracts (LBAs) will be showcased, accounting for nearly half of all oral presentations (45 in total) within the uro-oncology track — a testament to…
-
ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan. As one of the most prestigious international conferences in the field of hematology, this year’s meeting gathered leading experts from around the world to engage in in-depth discussions on the latest advances…
-
iwCLL 2025 | Dr. Alba Garrote-de-Barros: Clinical and Biological Implications of MYC Overexpression in CLL With or Without TP53 Dysfunction
Oncology Frontier – Hematology Frontier: Your study suggests that MYC overexpression correlates with worse prognosis in TP53 wild-type patients, while MYC overexpression in TP53-affected patients does not show significant prognostic…
-
ISEH 2025 | Professor Fumio Arai: Regulatory Mechanisms of Hematopoietic Stem Cell Quiescence and Their Clinical Translation Prospects
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan, bringing together leading global experts in hematology to discuss cutting-edge advances in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the major highlights of the event was…
-
Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference
Editor’s Note:In recent years, new diagnostic and therapeutic innovations in renal cancer have continued to emerge, providing clinicians with a growing range of treatment options. The widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled patients to achieve both oncological control and functional preservation. During the 2025 Pujiang Uro-Oncology Academic Conference, leading domestic and international…
-
Professor Wei Qiang: Advancing Innovation Across the Entire Continuum of Uro-Oncology Care and Making Robots Trusted Surgical Partners | 2025 Pujiang Uro-Oncology Academic Conference
The 2025 Pujiang Uro-Oncology Academic Conference was successfully held in Shanghai on August 22–23, 2025. Centered on the theme “Precision Breakthroughs · Integrated Innovation · Optimized Continuum of Care,” the conference brought together numerous domestic and international experts to explore innovation in uro-oncology diagnosis and treatment, multidisciplinary collaboration (MDT), and translational research. Oncology Frontier –…
Connecting Medical Expertise through Media